CR11333A - cis-IMIDAZOLINAS QUIRALES - Google Patents

cis-IMIDAZOLINAS QUIRALES

Info

Publication number
CR11333A
CR11333A CR11333A CR11333A CR11333A CR 11333 A CR11333 A CR 11333A CR 11333 A CR11333 A CR 11333A CR 11333 A CR11333 A CR 11333A CR 11333 A CR11333 A CR 11333A
Authority
CR
Costa Rica
Prior art keywords
quirales
imirazolinas
cis
compounds
obtaining
Prior art date
Application number
CR11333A
Other languages
English (en)
Inventor
David Joseph Bartkovitz
Jianping Cai
Xin-Jie Chu
Hongju Li
Allen John Lovey
Binh Thanh Vu
Chunlin Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40149549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11333(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR11333A publication Critical patent/CR11333A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan compuestos de la formula o sus sales farmaceuticamente aceptables, en la que X, Y,Z, V1, V2, R1, R2, R3, R4, y R5, tienen los significados aqui descritos, procesos para obtener dichos compuestos y preparaciones farmaceuticas que los contienen.
CR11333A 2007-10-09 2010-03-24 cis-IMIDAZOLINAS QUIRALES CR11333A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97850607P 2007-10-09 2007-10-09
US9275908P 2008-08-29 2008-08-29

Publications (1)

Publication Number Publication Date
CR11333A true CR11333A (es) 2010-06-21

Family

ID=40149549

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11333A CR11333A (es) 2007-10-09 2010-03-24 cis-IMIDAZOLINAS QUIRALES

Country Status (20)

Country Link
US (1) US8513239B2 (es)
EP (2) EP2203437B1 (es)
JP (1) JP5324586B2 (es)
KR (1) KR101203020B1 (es)
CN (2) CN101821251A (es)
AR (1) AR068742A1 (es)
AU (1) AU2008309759A1 (es)
BR (1) BRPI0817850A2 (es)
CA (1) CA2701932C (es)
CL (1) CL2008002982A1 (es)
CO (1) CO6280486A2 (es)
CR (1) CR11333A (es)
ES (1) ES2395210T3 (es)
IL (1) IL204653A0 (es)
MA (1) MA31754B1 (es)
MX (1) MX2010003868A (es)
PE (1) PE20090814A1 (es)
RU (1) RU2487127C2 (es)
TW (1) TW200916446A (es)
WO (1) WO2009047161A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2375899B1 (en) * 2009-01-12 2015-02-25 Array Biopharma Inc. Piperidine-containing compounds and use thereof in the treatment of diabetes
WO2010132873A2 (en) 2009-05-15 2010-11-18 Northwestern University Chiral pyrrolidine core compounds en route to inhibitors of nitric oxide synthase
WO2011073154A1 (en) 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists and uses thereof
WO2011073155A1 (en) 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh Novel antagonists for ccr2 and uses thereof
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US9266860B2 (en) 2010-09-30 2016-02-23 St. Jude Children's Research Hospital Aryl-substituted imidazoles
JP2014507384A (ja) * 2010-12-16 2014-03-27 ロシュ グリクアート アーゲー Ｍｄｍ２阻害剤とのアフコシル化ｃｄ２０抗体の併用療法
AU2012316055B2 (en) 2011-09-27 2016-05-12 Amgen Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
WO2014082889A1 (en) * 2012-11-28 2014-06-05 F. Hoffmann-La Roche Ag Novel imidazolines as dual inhibitors of mdm2 and mdmx
EP2935263B1 (en) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
CA2902856C (en) 2013-02-28 2021-02-16 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
HRP20191860T1 (hr) 2013-03-13 2019-12-27 Forma Therapeutics, Inc. Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodni spojevi kao inhibitori sintaze masnih kiselina (fasn) za liječenje raka
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
MA53572A1 (fr) 2013-06-10 2021-10-29 Amgen Inc Procédés de production et formes cristallines d'un inhibiteur mdm2
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN105906610B (zh) * 2016-05-24 2018-10-23 绍兴文理学院 一种3-（4-苯基-1h-咪唑-5-基）-1h-吲哚衍生物及其制备方法和应用
EP3415802B1 (en) 2017-06-14 2019-08-28 Borealis AG Expansion joint
CN117186108B (zh) * 2018-03-26 2025-08-19 诺华股份有限公司 布鲁顿酪氨酸激酶降解剂
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
AU2020315605A1 (en) 2019-07-16 2022-03-03 MyoKardia, Inc. Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide
EP4146645B1 (en) * 2020-05-07 2025-06-25 ONO Pharmaceutical Co., Ltd. 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
JP7743829B2 (ja) * 2021-11-05 2025-09-25 小野薬品工業株式会社 Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02101065A (ja) 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
GB2351082A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines
CN100486969C (zh) 2001-12-18 2009-05-13 霍夫曼-拉罗奇有限公司 顺式-2,4,5-三苯基-咪唑啉及其在肿瘤治疗中的应用
PL370909A1 (en) * 2001-12-18 2005-05-30 F.Hoffmann-La Roche Ag Cis-imidazolines as mdm2 inhibitors
EP1753727B1 (en) 2004-05-18 2008-11-19 F.Hoffmann-La Roche Ag Novel cis-imidazolines
WO2007006301A1 (en) 2005-07-08 2007-01-18 Vestas Wind Systems A/S A wind turbine, a hub for a wind turbine and use hereof
KR20100129331A (ko) * 2005-12-01 2010-12-08 에프. 호프만-라 로슈 아게 항암제로서 사용하기 위한 ｐ53 및 ｍｄｍ2 단백질 간 상호작용의 저해제로서의 2,4,5-트리페닐 이미다졸린 유도체
WO2007082805A1 (en) * 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors

Also Published As

Publication number Publication date
US20090111789A1 (en) 2009-04-30
EP2325180A1 (en) 2011-05-25
MX2010003868A (es) 2010-04-27
CO6280486A2 (es) 2011-05-20
CL2008002982A1 (es) 2009-10-16
KR20100051742A (ko) 2010-05-17
CN104710408A (zh) 2015-06-17
RU2487127C2 (ru) 2013-07-10
WO2009047161A1 (en) 2009-04-16
EP2203437B1 (en) 2012-11-07
PE20090814A1 (es) 2009-06-27
CN101821251A (zh) 2010-09-01
KR101203020B1 (ko) 2012-11-20
AR068742A1 (es) 2009-12-02
ES2395210T3 (es) 2013-02-11
JP5324586B2 (ja) 2013-10-23
IL204653A0 (en) 2010-11-30
CA2701932A1 (en) 2009-04-16
AU2008309759A1 (en) 2009-04-16
JP2010540675A (ja) 2010-12-24
US8513239B2 (en) 2013-08-20
MA31754B1 (fr) 2010-10-01
EP2203437A1 (en) 2010-07-07
TW200916446A (en) 2009-04-16
BRPI0817850A2 (pt) 2015-04-07
CA2701932C (en) 2015-10-20
RU2010118018A (ru) 2011-11-20

Similar Documents

Publication Publication Date Title
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
DOP2009000257A (es) Inhibidores de cinasa p70 s6
CL2019001993A1 (es) Inhibidores selectivos de jak1.
ECSP20003147A (es) Carboxamidas como moduladores de los canales de sodio
UY30681A1 (es) Compuestos de piridinamida que contienen carboxi, sales farmacéuticamente aceptables, procedimientos para la preparacion de los mismos, composiciones que los contienen y sus usos.
MX2017013886A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
UY30977A1 (es) Derivados de isoindolinas 4' -o-sustituidas. composiciones que las contienen y metodos para sus usos.
CO7141456A2 (es) Derivados de aril-sultamo como moduladores de rorc
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
ECSP088296A (es) Compuestos terapéuticos
UY30460A1 (es) Compuestos terapéuticos
CR11641A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
CR10148A (es) Derivados de las benzamidas y heteroarenos
CO6511251A2 (es) Compuestos quimicos
UY32649A (es) "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato"
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
AR063027A1 (es) Derivados de sulfonamida
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)